Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) have rallied back from the patent cliff as well as any companies in big pharma, and both these standout firms have looked toward the future in igniting investor optimism. But one drug captured all the hype around these two companies before its approval in the final days of 2012: blood thinner Eliquis.
Yet Eliquis hasn't met those high hopes in its first full year on the market. The drug's managed tepid sales at best, and Wall Street analysts have toned down 2014's expectations for Eliquis, a drug that once garnered peak sales estimates of up to $4 billion annually. Bristol and Pfizer aren't giving up on this promising yet sluggish therapy, but will Eliquis turn things around for investors cautious about the drug's future?
Eliquis's most recent approval might be the first spark of hope for this drug after a slow market debut. Find out how this promising drug can mount a comeback in the video below, as Motley Fool contributor Dan Carroll takes you through the latest on Eliquis -- and whether or not Pfizer, Bristol, and investors can rely on this ballyhooed medication to emerge as a blockbuster powerhouse in the future.
Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.